Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to -$17.6 million.

  • LifeStance Health's Change in Accured Expenses fell 7816.17% to -$17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 9617.36%. This contributed to the annual value of $15.0 million for FY2024, which is 4342.24% down from last year.
  • As of Q3 2025, LifeStance Health's Change in Accured Expenses stood at -$17.6 million, which was down 7816.17% from $29.3 million recorded in Q2 2025.
  • LifeStance Health's 5-year Change in Accured Expenses high stood at $58.3 million for Q3 2023, and its period low was -$39.1 million during Q4 2023.
  • For the 5-year period, LifeStance Health's Change in Accured Expenses averaged around $4.7 million, with its median value being $4.9 million (2022).
  • In the last 5 years, LifeStance Health's Change in Accured Expenses surged by 464645.67% in 2024 and then plummeted by 73138.95% in 2025.
  • LifeStance Health's Change in Accured Expenses (Quarter) stood at $26.5 million in 2021, then crashed by 125.34% to -$6.7 million in 2022, then crashed by 481.95% to -$39.1 million in 2023, then surged by 112.16% to $4.8 million in 2024, then plummeted by 469.97% to -$17.6 million in 2025.
  • Its last three reported values are -$17.6 million in Q3 2025, $29.3 million for Q2 2025, and -$17.5 million during Q1 2025.